glp-1 and kidney receptor agonists next-generation metabolic hormone therapies in chronic disease RACGP - GLP-1 receptor agonists

Newer JAK inhibitors (tofacitinib, upadacitinib) and S1P modulators (ozanimod) offer additional options

IV treatments are used for their unparalleled effectiveness for delivering nutrients to the body in a form optimized for 100% absorption and bioavailability

While many studies have highlighted the benefits of antioxidants, there is a need for long-term research to assess their safety and efficacy

If you clock at 200 kg and loose 20 kg (10% of your body weight) you now weigh 180kg

Be wary of prices that seem too good to be true

Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes